JP2022115876A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022115876A5 JP2022115876A5 JP2022070213A JP2022070213A JP2022115876A5 JP 2022115876 A5 JP2022115876 A5 JP 2022115876A5 JP 2022070213 A JP2022070213 A JP 2022070213A JP 2022070213 A JP2022070213 A JP 2022070213A JP 2022115876 A5 JP2022115876 A5 JP 2022115876A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- cancer
- seq
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000037865 fusion proteins Human genes 0.000 claims 26
- 108020001507 fusion proteins Proteins 0.000 claims 26
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 108010002350 Interleukin-2 Proteins 0.000 claims 6
- 108700004922 F42A Proteins 0.000 claims 5
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 5
- 102220596838 Non-structural maintenance of chromosomes element 1 homolog_R38A_mutation Human genes 0.000 claims 5
- 102220495631 Putative uncharacterized protein LOC645739_F42A_mutation Human genes 0.000 claims 5
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 239000013636 protein dimer Substances 0.000 claims 4
- 208000035473 Communicable disease Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- 102220505697 Palmitoyl-protein thioesterase 1_Y45F_mutation Human genes 0.000 claims 2
- 102220610852 Thialysine N-epsilon-acetyltransferase_L72G_mutation Human genes 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000009608 Papillomavirus Infections Diseases 0.000 claims 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims 1
- 206010034811 Pharyngeal cancer Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims 1
- 206010061934 Salivary gland cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 239000000710 homodimer Substances 0.000 claims 1
- 208000021145 human papilloma virus infection Diseases 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20180110698 | 2018-09-17 | ||
| KR10-2018-0110698 | 2018-09-17 | ||
| KR10-2019-0001867 | 2019-01-07 | ||
| KR20190001867 | 2019-01-07 | ||
| US201962832013P | 2019-04-10 | 2019-04-10 | |
| US62/832,013 | 2019-04-10 | ||
| KR20190053436 | 2019-05-08 | ||
| KR10-2019-0053436 | 2019-05-08 | ||
| JP2020562067A JP7085644B2 (ja) | 2018-09-17 | 2019-09-16 | Ｉｌ－２タンパク質およびｃｄ８０タンパク質を含む融合タンパク質およびその使用 |
| PCT/KR2019/011928 WO2020060122A1 (ko) | 2018-09-17 | 2019-09-16 | Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 이의 용도 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020562067A Division JP7085644B2 (ja) | 2018-09-17 | 2019-09-16 | Ｉｌ－２タンパク質およびｃｄ８０タンパク質を含む融合タンパク質およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022115876A JP2022115876A (ja) | 2022-08-09 |
| JP2022115876A5 true JP2022115876A5 (enExample) | 2022-09-20 |
| JP7569820B2 JP7569820B2 (ja) | 2024-10-18 |
Family
ID=69887592
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020562067A Active JP7085644B2 (ja) | 2018-09-17 | 2019-09-16 | Ｉｌ－２タンパク質およびｃｄ８０タンパク質を含む融合タンパク質およびその使用 |
| JP2022070213A Active JP7569820B2 (ja) | 2018-09-17 | 2022-04-21 | Ｉｌ－２タンパク質およびｃｄ８０タンパク質を含む融合タンパク質およびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020562067A Active JP7085644B2 (ja) | 2018-09-17 | 2019-09-16 | Ｉｌ－２タンパク質およびｃｄ８０タンパク質を含む融合タンパク質およびその使用 |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US11492384B2 (enExample) |
| EP (2) | EP3715367B1 (enExample) |
| JP (2) | JP7085644B2 (enExample) |
| KR (2) | KR102201086B1 (enExample) |
| CN (2) | CN118725141A (enExample) |
| AU (1) | AU2019343850B2 (enExample) |
| CA (1) | CA3086486A1 (enExample) |
| CL (1) | CL2020001872A1 (enExample) |
| DK (1) | DK3715367T3 (enExample) |
| ES (1) | ES2985387T3 (enExample) |
| FI (1) | FI3715367T3 (enExample) |
| HU (1) | HUE068059T2 (enExample) |
| IL (1) | IL275592B (enExample) |
| MX (1) | MX2020007072A (enExample) |
| PE (1) | PE20201418A1 (enExample) |
| PH (1) | PH12020551026A1 (enExample) |
| PL (1) | PL3715367T3 (enExample) |
| PT (1) | PT3715367T (enExample) |
| SG (1) | SG11202005873QA (enExample) |
| TW (2) | TWI824258B (enExample) |
| WO (1) | WO2020060122A1 (enExample) |
| ZA (1) | ZA202003645B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI640536B (zh) * | 2016-06-20 | 2018-11-11 | 克馬伯有限公司 | 抗體 |
| CA3086486A1 (en) * | 2018-09-17 | 2020-03-26 | Gi Innovation, Inc. | Fusion protein comprising il-2 protein and cd80 protein, and use thereof |
| KR102351020B1 (ko) | 2019-11-20 | 2022-01-14 | 주식회사 지아이셀 | 자연살해세포 배양용 조성물 및 이를 이용한 자연살해세포 제조방법 |
| IL292934A (en) | 2019-11-20 | 2022-07-01 | Gi Cell Inc | Composition of medium for t-cell culture and method for culture of t-cells using the same composition of medium |
| JP7488337B2 (ja) * | 2019-11-27 | 2024-05-21 | ジーアイ・セル・インコーポレイテッド | Ｉｌ－２タンパク質及びｃｄ８０タンパク質を含む融合タンパク質及びｎｋ細胞を含む抗癌治療用組成物 |
| US20230014358A1 (en) * | 2019-11-27 | 2023-01-19 | Gi Cell, Inc. | Composition for anticancer treatment, comprising nk cells and fusion protein which comprises il-2 protein and cd80 protein |
| MX2022011154A (es) | 2020-03-18 | 2022-10-13 | Gi Innovation Inc | Composicion farmaceutica para el tratamiento de cancer que comprende proteina de fusion que se compone de proteina il-2 y proteina cd80 y farmaco anticancerigeno. |
| US20230125871A1 (en) | 2020-03-18 | 2023-04-27 | Gi Innovation, Inc. | Fusion protein preparation comprising il-2 and cd80 proteins |
| US20230139890A1 (en) * | 2020-03-18 | 2023-05-04 | Gi Innovation, Inc. | Fusion protein comprising il-2 protein and cd80 protein fragment or variant thereof, and uses thereof |
| MX2022011893A (es) * | 2020-03-31 | 2022-10-18 | Hanmi Pharm Ind Co Ltd | Nuevos analogos de il-2 inmunoestimuladores. |
| AU2021282053A1 (en) * | 2020-05-25 | 2023-01-19 | Beijing Beyond Biotechnology Co., Ltd | Fc-CD80 fusion protein and conjugate thereof, and use thereof |
| KR102373965B1 (ko) * | 2020-06-05 | 2022-03-15 | (주)지아이이노베이션 | Ｉｌ-２ 단백질 및 ｃｄ８０ 단백질을 포함하는 융합단백질을 포함하는 방사선 치료 증진용 약학적 조성물 |
| US20230257438A1 (en) * | 2020-06-30 | 2023-08-17 | Gi Innovation, Inc. | Fusion protein comprising anti-lag-3 antibody and il-2, and use thereof |
| CA3184618A1 (en) * | 2020-07-02 | 2022-01-06 | John C. Timmer | Polypeptides comprising modified il-2 polypeptides and uses thereof |
| JP2023540296A (ja) * | 2020-08-31 | 2023-09-22 | ジーアイ・セル・インコーポレイテッド | ＩＬ１５タンパク質、ＩＬ１５受容体アルファタンパク質、Ｆｃドメイン及びＩＬ２タンパク質を含む融合タンパク質並びにその用途 |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| WO2022125387A1 (en) * | 2020-12-08 | 2022-06-16 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Anti-egfr chimeric antigen receptors |
| WO2022192898A2 (en) * | 2021-03-10 | 2022-09-15 | Immunowake Inc. | Immunomodulatory molecules and uses thereof |
| WO2022057696A2 (zh) * | 2021-09-08 | 2022-03-24 | 中南大学湘雅医院 | 一种重组蛋白的编码序列、重组蛋白及其单克隆抗体的制备方法 |
| KR20230168273A (ko) * | 2022-06-03 | 2023-12-13 | (주)지아이이노베이션 | 항-tigit 항체를 포함하는 이중 특이적 항체 및 이의 용도 |
| CN118974093A (zh) * | 2022-06-22 | 2024-11-15 | Gi 医诺微新 | 包含抗cd73抗体和il-2的融合蛋白及其用途 |
| KR102669111B1 (ko) * | 2022-09-20 | 2024-06-10 | 주식회사 지아이바이옴 | 락토바실러스 플란타룸 균주의 병용 요법 및 이를 이용한 암 치료 방법 |
| WO2024063546A1 (ko) | 2022-09-20 | 2024-03-28 | 주식회사 지아이바이옴 | 락토바실러스 플란타룸 균주의 병용 요법 및 이를 이용한 암 치료 방법 |
| CN115850436B (zh) * | 2022-10-14 | 2026-02-03 | 海徕科(北京)生物技术有限公司 | 白介素2突变体及其应用 |
| WO2025063755A1 (ko) * | 2023-09-20 | 2025-03-27 | 주식회사 에스엘바이젠 | 항암 dna 백신 및 면역반응-증진용 융합단백질을 포함하는 신규 암 치료제 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA842025B (en) * | 1983-03-21 | 1984-11-28 | Hoffmann La Roche | Interleuken-2 |
| CN86104525A (zh) * | 1985-07-31 | 1987-02-25 | 武田药品工业株式会社 | 人类白细胞介素-2的分析方法和试剂 |
| US5229109A (en) | 1992-04-14 | 1993-07-20 | Board Of Regents, The University Of Texas System | Low toxicity interleukin-2 analogues for use in immunotherapy |
| US6955807B1 (en) | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
| DZ2788A1 (fr) * | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
| GB9810999D0 (en) | 1998-05-21 | 1998-07-22 | Goken Joop | Materials and methods relating to the expression of genes |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| EP1476180A4 (en) * | 2001-08-13 | 2005-04-20 | Univ Southern California | MUTANTS OF INTERLEUKIN-2 WITH REDUCED TOXICITY |
| BR0214650A (pt) * | 2001-12-04 | 2005-05-03 | Merck Patent Gmbh | Imunocitoquinas com seletividade modulada |
| CU23229A1 (es) | 2002-05-10 | 2007-09-26 | Ct Ingenieria Genetica Biotech | ANTAGONISTA QUIMéRICO ANTH1 |
| WO2005091956A2 (en) * | 2004-03-05 | 2005-10-06 | Chiron Corporation | In vitro test system for predicting patient tolerability of therapeutic agents |
| EP2402754B2 (en) * | 2006-03-06 | 2023-07-26 | Amunix Operating Inc. | Unstructured recombinant polymers and uses thereof |
| CA2656700A1 (en) * | 2006-07-06 | 2008-01-10 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Compositions and methods for enhancing the efficacy of il-2 mediated immune responses |
| CN103298935A (zh) * | 2007-08-15 | 2013-09-11 | 阿穆尼克斯公司 | 用于改善生物活性多肽性能的组合物和方法 |
| CU23923B1 (es) | 2010-11-12 | 2013-07-31 | Ct De Inmunología Molecular | Polipéptidos derivados de la il-2 con actividad agonista |
| US9266938B2 (en) | 2011-02-10 | 2016-02-23 | Roche Glycart Ag | Mutant interleukin-2 polypeptides |
| EA201892619A1 (ru) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| US8956619B2 (en) * | 2011-10-25 | 2015-02-17 | University Of Maryland, Baltimore County | Soluble CD80 as a therapeutic to reverse immune supression in cancer patients |
| CA2904528C (en) * | 2013-03-15 | 2021-01-19 | Abbvie Biotherapeutics Inc. | Fc variants |
| WO2016030350A1 (en) * | 2014-08-29 | 2016-03-03 | F. Hoffmann-La Roche Ag | Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1 |
| CA3001131A1 (en) | 2015-11-02 | 2017-05-11 | Five Prime Therapeutics, Inc. | Cd80 extracellular domain polypeptides and their use in cancer treatment |
| CN109071623B (zh) * | 2016-05-04 | 2022-05-27 | 美国安进公司 | 用于扩增t调节性细胞的白细胞介素-2突变蛋白 |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| TWI640536B (zh) * | 2016-06-20 | 2018-11-11 | 克馬伯有限公司 | 抗體 |
| KR20190121816A (ko) | 2017-04-03 | 2019-10-28 | 에프. 호프만-라 로슈 아게 | 항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체 |
| CA3086486A1 (en) | 2018-09-17 | 2020-03-26 | Gi Innovation, Inc. | Fusion protein comprising il-2 protein and cd80 protein, and use thereof |
-
2019
- 2019-09-16 CA CA3086486A patent/CA3086486A1/en active Pending
- 2019-09-16 ES ES19862449T patent/ES2985387T3/es active Active
- 2019-09-16 SG SG11202005873QA patent/SG11202005873QA/en unknown
- 2019-09-16 EP EP19862449.6A patent/EP3715367B1/en active Active
- 2019-09-16 HU HUE19862449A patent/HUE068059T2/hu unknown
- 2019-09-16 EP EP24175556.0A patent/EP4403635A3/en active Pending
- 2019-09-16 PT PT198624496T patent/PT3715367T/pt unknown
- 2019-09-16 CN CN202410942368.3A patent/CN118725141A/zh active Pending
- 2019-09-16 PE PE2020000980A patent/PE20201418A1/es unknown
- 2019-09-16 PL PL19862449.6T patent/PL3715367T3/pl unknown
- 2019-09-16 WO PCT/KR2019/011928 patent/WO2020060122A1/ko not_active Ceased
- 2019-09-16 MX MX2020007072A patent/MX2020007072A/es unknown
- 2019-09-16 JP JP2020562067A patent/JP7085644B2/ja active Active
- 2019-09-16 FI FIEP19862449.6T patent/FI3715367T3/fi active
- 2019-09-16 AU AU2019343850A patent/AU2019343850B2/en active Active
- 2019-09-16 KR KR1020190113659A patent/KR102201086B1/ko active Active
- 2019-09-16 DK DK19862449.6T patent/DK3715367T3/da active
- 2019-09-16 US US16/959,312 patent/US11492384B2/en active Active
- 2019-09-16 CN CN201980025699.8A patent/CN111971295B/zh active Active
- 2019-09-17 TW TW110122590A patent/TWI824258B/zh active
- 2019-09-17 TW TW108133398A patent/TWI755630B/zh active
-
2020
- 2020-06-17 ZA ZA2020/03645A patent/ZA202003645B/en unknown
- 2020-06-22 IL IL275592A patent/IL275592B/en unknown
- 2020-06-30 PH PH12020551026A patent/PH12020551026A1/en unknown
- 2020-07-14 CL CL2020001872A patent/CL2020001872A1/es unknown
-
2021
- 2021-01-05 KR KR1020210000775A patent/KR102558191B1/ko active Active
-
2022
- 2022-04-21 JP JP2022070213A patent/JP7569820B2/ja active Active
- 2022-08-01 US US17/878,664 patent/US12291555B2/en active Active
- 2022-08-01 US US17/878,703 patent/US12286464B2/en active Active
-
2025
- 2025-04-01 US US19/097,579 patent/US20250230212A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022115876A5 (enExample) | ||
| FI3715367T3 (fi) | Il-2-proteiinia ja cd80-proteiinia sisältävä fuusioproteiini ja sen käyttö | |
| JP3820105B2 (ja) | Ｍｐ１受容体に結合し血小板生成活性を有する二量体トロンボポエチンペプチド模倣体 | |
| RU2012107671A (ru) | Композиция для лечения инфекции вирусом гепатита в | |
| JP2020515640A5 (enExample) | ||
| CN104039833A (zh) | 针对hpv的疫苗 | |
| JP2011525363A5 (enExample) | ||
| JP2015518479A5 (enExample) | ||
| JP2015509707A5 (enExample) | ||
| US20230242627A1 (en) | Composition and method for activating latent human immunodeficiency virus (hiv) | |
| US20140234316A1 (en) | Vaccibodies targeted to cross-presenting dendritic cells | |
| KR20230084478A (ko) | 면역원성 코로나 바이러스 융합 단백질 및 관련 방법 | |
| CN102311500B (zh) | 一种抗病毒融合蛋白及其应用 | |
| JP2021509254A (ja) | Ｈ３ｎ２亜型インフルエンザウイルスのヘマグルチニンタンパク質の突然変異体及びその使用 | |
| US20060233742A1 (en) | Peptides for the treatment of cancer associated with human papilloma virus (hpv) and other epithelial tumours | |
| JP6994714B2 (ja) | 抗ウイルス性ペプチドおよびその利用 | |
| TWI905155B (zh) | 包含 il-2蛋白及cd80蛋白片段或其變異體的融合蛋白及其用途 | |
| JPWO2017096432A5 (enExample) | ||
| WO2018219301A1 (zh) | 一种PDGFRβ靶向性肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途 | |
| CN101880327A (zh) | 蝎镇痛抗肿瘤缬精甘肽融合体及其获得方法 | |
| WO2015090234A1 (en) | Improving pharmacokinetic profile for angiopoietin-2 inhibiting polypeptide or thymalfasin | |
| JP2023522423A (ja) | インターフェロンアルファ２バリアント及びその使用 | |
| US20230140025A1 (en) | Vectors for Producing Virus-Like Particles and Uses Thereof | |
| US11028132B1 (en) | Half-life optimized linker composition | |
| AU2018342997B2 (en) | Cutaneous papilloma virus vaccine |